Haemacure obtains authorization to sell assets to Angiotech Pharmaceuticals

Haemacure Corporation (TSX:HAE) announces that it has obtained authorization from the Superior Court of the Province of Québec to sell its assets to Angiotech Pharmaceuticals, Inc., a secured creditor of Haemacure. The United States Bankruptcy Court previously authorized the sale to Angiotech of the assets of Haemacure's U.S. subsidiary.

The sale of the assets was concluded after a thorough bid-solicitation process carried out on behalf of Haemacure by PricewaterhouseCoopers Inc. in Canada and the United States, in the context of the notice of intention to make a proposal to its creditors filed by Haemacure on January 8, 2010 under the Bankruptcy and Insolvency Act (Canada).

Haemacure also obtained a second extension, until April 19, 2010, within which to make a proposal to its creditors. This extension will also allow Haemacure and Angiotech to complete the documentation required for the closing of the asset-sale transactions in Canada and the United States. The closings are expected to be held prior to the new expiry date of April 19, 2010.

Source:

HAEMACURE CORPORATION

Posted in:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Trump exaggerates speed and certainty of prescription drug price reductions